The government won a lawsuit filed by the government and the pharmaceutical industry over the cost-responsibility issue of follow-up measures for impurity drugs.

On the 9th, the Civil Affairs Division 21 of the Seoul Central District Court sided with the NHIS in a lawsuit filed by Daewon Pharmaceutical and 35 other companies against the NHIS. Pharmaceutical companies participating in the lawsuit must pay each reimbursement claimed by the NHIS unless they appeal separately. In addition, pharmaceutical companies must pay for the litigation.

The case originated when the NHIS claimed reimbursement from 69 pharmaceutical companies in October 2019. The total amount of compensation was 2.03 bil